These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 28067741)

  • 1. Hypertensive Medications in Competitive Athletes.
    Pelto H
    Curr Sports Med Rep; 2017; 16(1):45-49. PubMed ID: 28067741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.
    Khan NA; McAlister FA; Lewanczuk RZ; Touyz RM; Padwal R; Rabkin SW; Leiter LA; Lebel M; Herbert C; Schiffrin EL; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; DeChamplain J; Pylypchuk G; Logan AG; Gledhill N; Petrella R; Campbell NR; Arnold M; Moe G; Hill MD; Jones C; Larochelle P; Ogilvie RI; Tobe S; Houlden R; Burgess E; Feldman RD;
    Can J Cardiol; 2005 Jun; 21(8):657-72. PubMed ID: 16003449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential impact of angiotensin receptor blockers and calcium channel blockers on arterial stiffness.
    Andreadis EA; Sfakianakis ME; Tsourous GI; Georgiopoulos DX; Fragouli EG; Katsanou PM; Tavoularis EI; Skarlatou MG; Marakomichelakis GE; Ifanti GK; Diamantopoulos EJ
    Int Angiol; 2010 Jun; 29(3):266-72. PubMed ID: 20502415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertension update and cardiovascular risk reduction in physically active individuals and athletes.
    Oliveira LP; Lawless CE
    Phys Sportsmed; 2010 Apr; 38(1):11-20. PubMed ID: 20424397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Assessment of antihypertensive monotherapies effectiveness by home blood pressure self-measurement in hypertensive patients].
    Hanon O; Laroche P; Vidal JS; Pannier B; Postel-Vinay N; Vaisse B; Girerd X
    Ann Cardiol Angeiol (Paris); 2012 Jun; 61(3):218-23. PubMed ID: 22695025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of hypertension in athletes: an evidence-based review.
    Asplund C
    Phys Sportsmed; 2010 Apr; 38(1):37-44. PubMed ID: 20424400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk of essential hypertension: influence of class, number, and treatment-time regimen of hypertension medications.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Chronobiol Int; 2013 Mar; 30(1-2):315-27. PubMed ID: 23181712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Choice of antihypertensive drug in the diabetic patient.
    Ong HT; Cheah JS
    MedGenMed; 2005 May; 7(2):74. PubMed ID: 16369452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of hypertension in chronic kidney disease.
    Toto RD
    Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating essential hypertension. The first choice is usually a thiazide diuretic.
    Prescrire Int; 2014 Sep; 23(152):215-20. PubMed ID: 25325125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
    Talbert RL
    J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Calcium antagonists: current and future applications based on new evidence. Calcium channel blockers and single-pill combination].
    Okura T; Higaki J
    Clin Calcium; 2010 Jan; 20(1):61-8. PubMed ID: 20048435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [How to use anti-hypertensive medication in management of diabetic patients].
    Hirose H; Saito I
    Nihon Rinsho; 2003 Jul; 61(7):1205-9. PubMed ID: 12877086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current recommendations for the treatment of hypertension: are they still valid?
    Moser M
    J Hypertens Suppl; 2002 Feb; 20(1):S3-10. PubMed ID: 11996197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcium channel blockers suppress daily variations of blood pressure in hypertensive patients with end-stage renal diseases.
    Takenaka T; Sueyoshi K; Arai J; Watanabe Y; Takane H; Ohno Y; Suzuki H
    Clin Exp Hypertens; 2014; 36(2):78-82. PubMed ID: 24625333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
    Petrella R; Michailidis P
    Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.